U.S. Retail REITs Stock News

NYSE:NOW
NYSE:NOWSoftware

ServiceNow AI Partnerships Deepen Role In Data Trust And Workflows

ServiceNow (NYSE:NOW) has announced new AI focused partnerships and platform integrations with Acceldata, Ataccama, Cloudera, and EPAM. These integrations embed data quality, observability, and governed data access directly into ServiceNow workflows for AI agents. The collaboration aims to support real time, autonomous AI execution across hybrid environments for enterprise customers. ServiceNow is trading at $93.59, with the stock up 6.0% over the past week but showing a 6.9% decline over...
NYSE:BCC
NYSE:BCCTrade Distributors

Is Boise Cascade (BCC) Fairly Priced After Recent Share Price Pullback?

If you are wondering whether Boise Cascade’s current share price offers good value, the recent share performance gives a useful starting point but not the full story. The stock last closed at US$72.76, with a 7 day return of 8.2% decline, a 30 day return of 2.6% decline, a year to date return of 1.8% decline, and a 1 year return of 17.9% decline, set against 3 year and 5 year returns of 14.9% and 35.5% respectively. Recent coverage has focused on Boise Cascade as part of evergreen analysis...
NasdaqGS:EXFY
NasdaqGS:EXFYSoftware

Expensify (EXFY) Losses Of US$21.4 Million TTM Challenge Profitability Narratives

Expensify (EXFY) just closed FY 2025 with fourth quarter revenue of US$35.2 million, a basic EPS loss of US$0.08 per share, and a quarterly net loss of US$7.1 million. On a trailing 12 month basis, the company recorded revenue of US$142.1 million and a net loss of US$21.4 million. Over recent quarters, revenue has moved in a tight band between US$35.1 million and US$37.0 million, while quarterly basic EPS has ranged from a loss of US$0.02 to US$0.10 per share. This has left investors focused...
NYSE:CTRE
NYSE:CTREHealth Care REITs

CareTrust REIT (CTRE) Margin Surge Reinforces Bullish Narratives Ahead Of FY 2025 Earnings

CareTrust REIT (CTRE) has wrapped up FY 2025 with fourth quarter revenue of US$134.9 million and basic EPS of US$0.50, setting the tone for a year where trailing twelve month revenue reached US$476.4 million and EPS came in at US$1.57. Over the past six reported quarters, revenue has moved from US$77.4 million in Q3 2024 to US$134.9 million in Q4 2025, while quarterly basic EPS has ranged from US$0.21 to US$0.50. This leaves investors focused on how these headline figures line up with the...
NYSE:ALTG
NYSE:ALTGTrade Distributors

Alta Equipment Group (ALTG) Losses Reinforce Bearish Narratives Despite Q4 Revenue Of US$509.1 Million

Alta Equipment Group (ALTG) has just posted another loss-making quarter, with Q4 FY 2025 revenue of US$509.1 million and basic EPS of a US$0.39 loss, while trailing twelve month revenue sits at US$1.84 billion and EPS at a US$2.55 loss. Over the past six reported quarters, revenue has moved within a range of US$422.6 million to US$509.1 million per quarter as losses have fluctuated between US$0.21 and US$1.31 per share, underscoring a business that is still working through margin pressure...
NasdaqGS:TXG
NasdaqGS:TXGLife Sciences

10x Genomics (TXG) Loss Reduction To US$0.35 TTM EPS Challenges Bearish Profitability Narrative

10x Genomics (TXG) closed out FY 2025 with Q4 revenue of US$166.0 million and a basic EPS loss of US$0.13, alongside trailing twelve month revenue of US$642.8 million and a TTM basic EPS loss of US$0.35. Over recent quarters, the company has seen revenue fluctuate between US$149.0 million and US$172.9 million, while quarterly basic EPS has moved between a loss of US$0.40 and a profit of US$0.28, highlighting an uneven path on the income line. For investors, the latest print keeps the focus on...
NasdaqGS:ARWR
NasdaqGS:ARWRBiotechs

Arrowhead Pharmaceuticals (ARWR) Q1 Profit Supports Bullish Narrative Despite High 54x P/E

Arrowhead Pharmaceuticals (ARWR) opened 2026 with Q1 revenue of US$264.0 million and basic EPS of US$0.22, while trailing twelve month figures show revenue of US$1.1 billion and basic EPS of US$1.48 as the company stayed in profitable territory over the last year. Over recent quarters, revenue has moved from US$2.5 million in Q1 2025 to US$542.7 million in Q2 2025 and US$256.5 million in Q4 2025, with EPS shifting from a loss of US$1.39 per share in Q1 2025 to a profit of US$2.78 per share in...
NasdaqGS:INSG
NasdaqGS:INSGCommunications

Inseego (INSG) Q4 EPS Loss Tests Bullish Thesis Of Narrowing Losses

Inseego (INSG) has wrapped up FY 2025 with fourth quarter revenue of US$48.4 million and a basic EPS loss of US$0.03, alongside net income from continuing operations of a US$0.46 million loss. Over recent quarters, the company has seen revenue move from US$31.7 million in Q1 2025 to US$45.9 million in Q3 2025 and then US$48.4 million in Q4 2025. Quarterly EPS shifted between a loss of US$0.14 in Q1 2025, a profit of US$0.03 in Q3 2025, and back to a small loss in Q4 2025. This sets up a story...
NasdaqCM:TCX
NasdaqCM:TCXIT

Tucows (TCX) TTM Loss Of US$75.8 Million Reinforces Bearish Profitability Narrative

Tucows (TCX) has just wrapped up FY 2025 with Q4 revenue of about US$98.7 million and a basic EPS loss of US$1.98, alongside a Q4 net loss of US$22.0 million. Over the past six quarters, revenue has moved from US$92.3 million in Q3 2024 to US$98.7 million in Q4 2025. Quarterly basic EPS has ranged from a loss of US$3.86 in Q4 2024 to a loss of US$1.98 in the latest quarter. Trailing twelve month EPS currently sits at a loss of US$6.85 on revenue of US$390.3 million as margins remain under...
NYSE:NGVC
NYSE:NGVCConsumer Retailing

Natural Grocers Q1 2026 Margin And EPS Strength Reinforces Bullish Narratives Despite Slower Sales

Q1 2026 earnings snapshot Natural Grocers by Vitamin Cottage (NGVC) opened fiscal 2026 with Q1 revenue of US$335.6 million and basic EPS of US$0.49, setting the tone for its latest earnings update. The company reported revenue of US$330.2 million and EPS of US$0.43 in Q1 2025, compared with US$335.6 million and EPS of US$0.49 in Q1 2026. Trailing twelve month EPS stands at US$2.08 on revenue of about US$1.3 billion, with higher net profit margins and earnings growth framing the quarter as one...
NYSE:ED
NYSE:EDIntegrated Utilities

Consolidated Edison (ED) Earnings Growth And 12% Margin Reinforce Bullish Narratives

Consolidated Edison (ED) has wrapped up FY 2025 with fourth quarter revenue of US$3,994 million and basic EPS of US$0.82, alongside trailing twelve month revenue of US$16.9 billion and basic EPS of US$5.66, set against earnings growth of 11.2% over the past year and an average 10.5% per year over five years. Over recent periods, the company has seen quarterly revenue range from US$3,595 million to US$4,798 million while basic EPS moved between US$0.68 and US$2.26, giving investors a clearer...
NYSE:GRNT
NYSE:GRNTOil and Gas

Granite Ridge Resources (GRNT) One Off Loss Drives Q4 EPS Hit Challenges Bullish Narratives

Granite Ridge Resources (GRNT) has wrapped up FY 2025 with fourth quarter revenue of US$100.4 million and a basic EPS loss of US$0.19. Trailing twelve month revenue came in at US$427.9 million and basic EPS of US$0.19, as net profit margin moved to 5.8% from 5.3% a year earlier and earnings growth of 29.9% over the past year. Over recent periods the company has seen revenue move from US$359.0 million in the twelve months to Q4 2024 to US$427.9 million in the twelve months to Q4 2025. Over the...
NasdaqGS:SSP
NasdaqGS:SSPMedia

Scripps (SSP) Quarterly Net Loss Deepens Cautious Narratives Despite Stable Revenue Base

E.W. Scripps (SSP) just reported FY 2025 fourth quarter results with revenue of US$560.3 million and basic EPS of US$0.51 loss, set against a year earlier fourth quarter that showed revenue of US$728.4 million and basic EPS of US$0.93. Over recent periods the company has seen quarterly revenue move from US$646.3 million and EPS of US$0.37 in 2024 Q3 to US$560.3 million and EPS of US$0.51 loss in 2025 Q4. Trailing 12 month revenue sits at about US$2.2 billion with basic EPS of US$1.87 loss...
NasdaqGS:CRNC
NasdaqGS:CRNCSoftware

Cerence (CRNC) Revenue Surges To US$115.1 Million Testing Bullish Growth Narratives

Cerence (CRNC) opened Q1 2026 with total revenue of US$115.1 million, Basic EPS of a US$0.12 loss, and net income excluding extra items of a US$5.2 million loss, while the trailing 12 months show Basic EPS of roughly US$0.01 and net income excluding extra items of about US$0.3 million. Over recent quarters the company has seen revenue move from US$50.9 million in Q1 2025 to US$115.1 million in Q1 2026, alongside Basic EPS shifting from a US$0.57 loss to a US$0.12 loss and trailing 12 month...
NYSE:MCY
NYSE:MCYInsurance

A Look At Mercury General (MCY) Valuation After Its First Quarter Earnings Turnaround

Earnings turnaround puts Mercury General in focus Mercury General (MCY) is back on many investors’ radars after first quarter results showed revenue of US$1,539.81 million and net income of US$190.42 million, compared with a net loss a year earlier. See our latest analysis for Mercury General. The earnings rebound and steady dividend news have come alongside a 1 month share price return of 8.67% and a 1 year total shareholder return of 74.37%, which together point to solid momentum rather...
NasdaqGS:SRPT
NasdaqGS:SRPTBiotechs

Is Sarepta Therapeutics (SRPT) A Potential Opportunity After Sharp Multi‑Year Share Price Declines?

If you are wondering whether Sarepta Therapeutics at US$20.80 is starting to look like value or still carries too much risk, the recent share price and fundamentals give you a lot to weigh up. The stock has been under pressure, with returns of 0.4% decline over 7 days, 9.9% decline over 30 days, 2.4% decline year to date, 43.0% decline over 1 year and 82.7% decline over 3 years, while the 5 year return sits at 71.3% decline. Recent news around Sarepta Therapeutics has focused on its position...
NYSE:NHI
NYSE:NHIHealth Care REITs

National Health Investors Refocuses Portfolio On Private Pay Senior Housing

National Health Investors (NYSE:NHI) is selling its entire skilled nursing facility portfolio for $560 million. The company plans to redeploy proceeds into private-pay senior housing, including a seven-property portfolio in Colorado. This shift reduces exposure to skilled nursing and increases focus on private-pay assets that management views as offering more attractive risk adjusted returns. For investors watching NYSE:NHI, this move comes with the stock recently closing at $75.07 and...
NasdaqCM:ORGO
NasdaqCM:ORGOBiotechs

Organogenesis Holdings (ORGO) Q4 EPS Rebound Tests Bullish Earnings Ramp Narrative

Organogenesis Holdings (ORGO) closed FY 2025 with fourth quarter revenue of US$225.6 million and basic EPS of US$0.28, alongside net income of US$35.1 million that capped a profitable trailing twelve month period. The company has seen quarterly revenue move from US$126.7 million and EPS of US$0.05 in Q4 2024 to US$225.6 million and EPS of US$0.28 in Q4 2025. Trailing twelve month EPS shifted from roughly flat at US$0.01 in Q4 2024 to US$0.16 in Q4 2025, setting up a results season where the...
NasdaqGS:PACB
NasdaqGS:PACBLife Sciences

Pacific Biosciences Of California (PACB) Q4 Loss Highlights Ongoing Break From Bullish Profitability Narratives

Pacific Biosciences of California (PACB) has just posted its FY 2025 numbers, with Q4 revenue at US$44.6 million and a basic EPS loss of US$0.13 set against trailing twelve month revenue of US$160.0 million and a TTM basic EPS loss of US$1.82. Over the past six reported quarters, the company has seen quarterly revenue move between US$37.2 million and US$44.6 million, while basic EPS has ranged from a small profit of US$0.01 in FY 2024 Q4 to a loss of US$1.44 in FY 2025 Q1. This leaves...
NYSE:GENI
NYSE:GENIHospitality

Genius Sports (GENI) Q1 Loss Widening To US$55 Million Tests Bullish Profitability Narratives

Genius Sports (GENI) opened Q1 2026 with revenue of US$188 million, a basic EPS loss of US$0.21 per share, and net income loss of US$55 million, setting a cautious tone around near term profitability. The company has seen quarterly revenue move from US$144 million in Q1 2025 to US$188 million in Q1 2026, while basic EPS shifted from a loss of US$0.03 to a loss of US$0.21 over the same period. This puts the focus squarely on how efficiently that extra revenue is translating into results. For...
NYSE:NSA
NYSE:NSASpecialized REITs

A Look At National Storage Affiliates (NSA) Valuation After Recent Share Price Momentum

Why National Storage Affiliates Trust is on investors’ radar National Storage Affiliates Trust (NSA) has drawn attention after its recent share performance, with the stock showing positive returns over the past week, month and past 3 months. This has invited closer inspection from income focused REIT investors. See our latest analysis for National Storage Affiliates Trust. While the 1 day share price return was slightly negative, the recent 30 day and year to date share price returns of...
NYSE:NKE
NYSE:NKELuxury

Is Nike’s Steady Dividend Amid Downgrades Altering The Investment Case For NIKE (NKE)?

In early May 2026, NIKE, Inc.’s board declared a quarterly cash dividend of US$0.41 per share on its Class A and Class B common stock, payable on July 1, 2026, to shareholders of record as of June 1, 2026. The dividend decision comes as Nike faces analyst downgrades, business headwinds, and legal and regulatory scrutiny that are testing confidence in its turnaround plan. Next, we’ll examine how Wells Fargo’s downgrade, tied to weaker athletic footwear demand and global challenges, reshapes...
NasdaqGS:ACAD
NasdaqGS:ACADBiotechs

Acadia Pharmaceuticals (ACAD) Margin Expansion To 34.3% Tests Bearish Growth Concerns

ACADIA Pharmaceuticals (ACAD) opened 2026 with Q1 revenue of $268.1 million and basic EPS of $0.02, against a backdrop of trailing twelve month revenue of $1.1 billion, basic EPS of $2.22 and net income of $375.7 million. Over recent quarters, the company has seen revenue move from $244.3 million in Q1 2025 to $268.1 million in Q1 2026, while quarterly basic EPS has ranged from $0.11 to $1.62. These results come within a period of margin expansion and earnings growth that investors now need...
NasdaqGS:OUST
NasdaqGS:OUSTElectronic

Is It Too Late To Consider Ouster (OUST) After Its 183% One Year Surge?

If you are wondering whether Ouster's share price still offers value after a strong run, it helps to start by lining up the recent returns with what the current valuation really implies. Ouster's stock closed at US$24.51, with returns of 26.8% over 30 days, 4.9% year to date and 183.4% over 1 year, while the last 7 days show a 9.1% decline and the 5 year figure sits at a 70.9% loss. Taken together, these figures suggest investors have been reassessing both potential and risk over different...